{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:46:28Z","timestamp":1791254788945,"version":"4.1.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:sec id=\"ab-noi230033-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230033-5\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the effectiveness and persistence of dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis (RRMS) who discontinued natalizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230033-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>In this observational cohort study, patient data were collected from the MSBase registry between June 15, 2010, and July 6, 2021. The median follow-up was 2.7 years. This was a multicenter study that included patients with RRMS who had used natalizumab for 6 months or longer and then were switched to dimethyl fumarate, fingolimod, or ocrelizumab within 3 months after natalizumab discontinuation. Patients without baseline data were excluded from the analysis. Data were analyzed from May 24, 2022, to January 9, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230033-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Dimethyl fumarate, fingolimod, and ocrelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230033-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Primary outcomes were annualized relapse rate (ARR) and time to first relapse. Secondary outcomes were confirmed disability accumulation, disability improvement, and subsequent treatment discontinuation, with the comparisons for the first 2 limited to fingolimod and ocrelizumab due to the small number of patients taking dimethyl fumarate. The associations were analyzed after balancing covariates using an inverse probability of treatment weighting method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230033-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 66\u202f840 patients with RRMS, 1744 had used natalizumab for 6 months or longer and were switched to dimethyl fumarate, fingolimod, or ocrelizumab within 3 months of natalizumab discontinuation. After excluding 358 patients without baseline data, a total of 1386 patients (mean [SD] age, 41.3 [10.6] years; 990 female [71%]) switched to dimethyl fumarate (138 [9.9%]), fingolimod (823 [59.4%]), or ocrelizumab (425 [30.7%]) after natalizumab. The ARR for each medication was as follows: ocrelizumab, 0.06 (95% CI, 0.04-0.08); fingolimod, 0.26 (95% CI, 0.12-0.48); and dimethyl fumarate, 0.27 (95% CI, 0.12-0.56). The ARR ratio of fingolimod to ocrelizumab was 4.33 (95% CI, 3.12-6.01) and of dimethyl fumarate to ocrelizumab was 4.50 (95% CI, 2.89-7.03). Compared with ocrelizumab, the hazard ratio (HR) of time to first relapse was 4.02 (95% CI, 2.83-5.70) for fingolimod and 3.70 (95% CI, 2.35-5.84) for dimethyl fumarate. The HR of treatment discontinuation was 2.57 (95% CI, 1.74-3.80) for fingolimod and 4.26 (95% CI, 2.65-6.84) for dimethyl fumarate. Fingolimod use was associated with a 49% higher risk for disability accumulation compared with ocrelizumab. There was no significant difference in disability improvement rates between fingolimod and ocrelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230033-10\">\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>Study results show that among patients with RRMS who switched from natalizumab to dimethyl fumarate, fingolimod, or ocrelizumab, ocrelizumab use was associated with the lowest ARR and discontinuation rates, and the longest time to first relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.1542","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:03:28Z","timestamp":1685963008000},"page":"739","source":"Crossref","is-referenced-by-count":42,"title":["Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation"],"prefix":"10.1001","volume":"80","author":[{"given":"Chao","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[{"name":"Charles University in Prague and General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Box Hill Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Box Hill Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[{"name":"Amiri Hospital, Sharq, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen Macarena, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eichau","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen Macarena, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Grand\u2019Maison","sequence":"additional","affiliation":[{"name":"Neuro Rive-Sud, Longueuil, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"Liverpool Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Grammond","sequence":"additional","affiliation":[{"name":"CISSS Chaudi\u00e8re-Appalache, Levis, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[{"name":"University Newcastle, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Butler","sequence":"additional","affiliation":[{"name":"Monash Medical Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[{"name":"CHUM MS Center and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Girard","sequence":"additional","affiliation":[{"name":"CHUM MS Center and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duquette","sequence":"additional","affiliation":[{"name":"CHUM MS Center and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A. L.","family":"Macdonell","sequence":"additional","affiliation":[{"name":"Austin Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[{"name":"Buffalo General Medical Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[{"name":"Dokuz Eylul University, Konak\/Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slee","sequence":"additional","affiliation":[{"name":"Flinders University, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Sa","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universitario de S\u00e3o Jo\u00e3o, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Van Pesch","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[{"name":"Brain and Mind Centre, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[{"name":"Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gerlach","sequence":"additional","affiliation":[{"name":"Zuyderland Medical Center, Sittard-Geleen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Prevost","sequence":"additional","affiliation":[{"name":"CSSS Saint-J\u00e9r\u00f4me, Saint-Jerome, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[{"name":"19 Mayis University, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit","family":"Boz","sequence":"additional","affiliation":[{"name":"KTU Medical Faculty Farabi Hospital, Trabzon, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[{"name":"Universitary Hospital Ghent, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Van Hijfte","sequence":"additional","affiliation":[{"name":"Universitary Hospital Ghent, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[{"name":"University of Western Australia, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Garber","sequence":"additional","affiliation":[{"name":"Westmead Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[{"name":"American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[{"name":"American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Merlo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MSBase Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P","family":"Leist","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily\u00a0","family":"Habib","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paarami\u00a0","family":"Udugama","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla\u00a0","family":"Gray","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana\u00a0","family":"Horakova","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte\u00a0","family":"Sartori","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein\u00a0","family":"More","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00a0","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela\u00a0","family":"Farr","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusko\u00a0","family":"Stupar","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia\u00a0","family":"Tang","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison\u00a0","family":"Le","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya\u00a0","family":"Smirnova","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurang\u00a0","family":"Palshetkar","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim\u00a0","family":"Spelman","sequence":"additional","affiliation":[{"name":"for the MSBase Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6364","key":"noi230033r1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"issue":"1","key":"noi230033r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-5728(94)00165-K","article-title":"A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis.","volume":"58","author":"Kent","year":"1995","journal-title":"J Neuroimmunol"},{"issue":"1","key":"noi230033r3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"noi230033r4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"noi230033r5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"noi230033r6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi230033r7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"noi230033r8","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"noi230033r9","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"issue":"14","key":"noi230033r10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse.","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"noi230033r11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.v76.6","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"issue":"4","key":"noi230033r12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","article-title":"Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMA Neurol"},{"issue":"8","key":"noi230033r13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"issue":"22","key":"noi230033r14","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1212\/WNL.0b013e31821d7553","article-title":"Interruption of natalizumab therapy for multiple sclerosis: what are the risks?","volume":"76","author":"Naismith","year":"2011","journal-title":"Neurology"},{"issue":"17","key":"noi230033r15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"noi230033r16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"noi230033r17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"noi230033r18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1352458514549404","article-title":"Relapses in patients treated with fingolimod after previous exposure to natalizumab.","volume":"21","author":"Comi","year":"2015","journal-title":"Mult Scler"},{"issue":"2","key":"noi230033r19","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/ane.2013.128.issue-2","article-title":"Switching from natalizumab to fingolimod: an observational study.","volume":"128","author":"Sempere","year":"2013","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"noi230033r20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/1352458517726381","article-title":"Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.","volume":"24","author":"Leurs","year":"2018","journal-title":"Mult Scler"},{"issue":"11","key":"noi230033r21","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1007\/s00415-019-09464-0","article-title":"Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.","volume":"266","author":"Guger","year":"2019","journal-title":"J Neurol"},{"issue":"12","key":"noi230033r22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/jnnp-2017-316236","article-title":"Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.","volume":"88","author":"Calabrese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"noi230033r23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000660","article-title":"Dimethyl fumarate vs fingolimod following different pretreatments: a retrospective study.","volume":"7","author":"Diem","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"noi230033r24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00415-016-8162-8","article-title":"Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.","volume":"263","author":"Zurawski","year":"2016","journal-title":"J Neurol"},{"issue":"5","key":"noi230033r25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/1352458520946017","article-title":"Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.","volume":"27","author":"Mancinelli","year":"2021","journal-title":"Mult Scler"},{"issue":"1","key":"noi230033r26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000904","article-title":"Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.","volume":"8","author":"Toorop","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"noi230033r27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"noi230033r28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000183","article-title":"Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.","volume":"3","author":"Gross","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"noi230033r29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab vs interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"noi230033r30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab vs placebo in primary progressive multiple sclerosis.","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"noi230033r31","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1212\/CPJ.0000000000000809","article-title":"Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice.","volume":"10","author":"Hersh","year":"2020","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"noi230033r32","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00415-021-10950-7","article-title":"Ocrelizumab vs fingolimod after natalizumab cessation in multiple sclerosis: an observational study.","volume":"269","author":"Bigaut","year":"2022","journal-title":"J Neurol"},{"issue":"6","key":"noi230033r33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Mult Scler"},{"issue":"5","key":"noi230033r34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/1352458516662728","article-title":"Data quality evaluation for observational multiple sclerosis registries.","volume":"23","author":"Kalincik","year":"2017","journal-title":"Mult Scler"},{"issue":"122","key":"noi230033r35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann N Y Acad Sci"},{"issue":"28","key":"noi230033r36","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.v34.28","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"noi230033r37","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/biomet\/87.3.706","article-title":"The role of the propensity score in estimating dose-response functions.","volume":"87","author":"Imbens","year":"2000","journal-title":"Biometrika"},{"issue":"2","key":"noi230033r38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"25","key":"noi230033r39","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"noi230033r40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/biomet\/67.1.145","article-title":"Chi-squared goodness-of-fit tests for the proportional hazards regression model.","volume":"67","author":"Schoenfeld","year":"1980","journal-title":"Biometrika"},{"issue":"7","key":"noi230033r41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/aje\/kwq474","article-title":"Invited commentary: G-computation\u2014lost in translation?","volume":"173","author":"Vansteelandt","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"4","key":"noi230033r42","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1177\/09622802211047345","article-title":"G-computation and doubly robust standardisation for continuous-time data: a comparison with inverse probability weighting.","volume":"31","author":"Chatton","year":"2022","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"noi230033r43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/aje\/kwq472","article-title":"Implementation of G-computation on a simulated data set: demonstration of a causal inference technique.","volume":"173","author":"Snowden","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"Pt 11","key":"noi230033r45","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod vs interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis.","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain"},{"issue":"9","key":"noi230033r46","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/art.v58:9","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study.","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"noi230033r47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jspi.2004.06.060","article-title":"Why prefer double robust estimators in causal inference?","volume":"129","author":"Neugebauer","year":"2005","journal-title":"J Stat Plan Inference"},{"issue":"1","key":"noi230033r48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0962280210386207","article-title":"Diagnosing and responding to violations in the positivity assumption.","volume":"21","author":"Petersen","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"noi230033r49","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419837809","article-title":"Postnatalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"noi230033r44","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Survey Nonresponse","author":"Rubin","year":"1987"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2805561\/jamaneurology_zhu_2023_oi_230033_1688145170.9612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T11:33:17Z","timestamp":1688988797000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2805561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.1542","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}